Our CEO, Martin Olin, comments on today’s Q1 2022 results. You can read the report in full here: #FinancialResults #BGBIO

Today we announced our Q1 2022 results. A presentation by BerGenBio’s senior management team will take place today at 10 am CEST - watch the webcast here: Read the full PR here: #FinancialResults

We’re pleased to announce complete data analysis from the #ACCORD2 phase II study of #bemcentinib in combination with #SoC therapy in hospitalized #COVID19 patients. The primary endpoint of improved clinical response was met. Read the full release here:

The data presented at #ECCMID2022 today demonstrate that bemcentinib treatment provides early and sustained protection, limiting clinical deterioration in moderate to severe #COVID19 patients. Read the full release here: #BGBIO #oncology #Presenation.

We’re presenting data from our BGBC020 clinical trial in hospitalised #COVID19 patients today at #ECCMID2022. Read the full release here:

Yesterday we announced a publication in Cell Reports Medicine on #AXL as a driver of immune suppression in STK11/LKB1 mutated NSCLC. STK11 is associated with poor treatment outcomes in NSCLC. There are currently no STK11-targeted therapies . Link:

BerGenBio’s CEO, Martin Olin, comments on today’s Q4 and FY 2021 results. You can view the report in full here: #financialresults #BGBIO

Today we announced our Q4 and FY 2021 #results. A presentation by BerGenBio’s senior management team will take place today at 10am CET. If you would like to watch the live webcast, follow this link: . Read the press release here:

We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial. Read the release here: #AXL

This morning BerGenBio announced a license agreement with @UTSWNews . The exclusive license is related to the treatment of Non-Small Cell Cancer (NSCLC) patients with #STK11 mutations and supports the Company’s existing IP position. Read here:

CEO Martin Olin comments on BerGenBio’s Q3 2021 results, out today. You can view the report in full here: #financialresults #BGBIO

We are pleased to announce our Q3 2021 results. A presentation by BerGenBio’s senior management team will take place today at 10am CET. For the full webcast: . For the full PR: #oncology #financialresults #BGBIO

Register to watch BerGenBio's Satellite Symposium taking place today at the EHA SWG at 17:30 CET here: #EHA #hematology

September is Blood Cancer Awareness Month. Blood cancer affects millions and BerGenBio shares the vision of raising awareness and understanding of blood cancers, including #AML, the most common form of acute leukaemia. Learn more here: #BCAM2021

Today we announced our financial results for the second quarter and first half of 2021. A presentation by BerGenBio's senior management team will take place today at 10:00 am CET at this link: Read the full announcement here:

Yesterday we were honoured to host @IselinNybo the Norwegian Minister of Trade and Industry, at BerGenBio - see some pictures from the visit below. #Norway #NorweiganBiotech #BGBIO

In case you missed it, our CEO Richard Godfrey commented on our exciting progress last week in this video – watch it on our website here: #CEOVideo #EHA #ECCMID #oncology.

Our CEO, Richard Godfrey, comments on a very exciting and encouraging week for #BerGenBio. To learn more about the progress we’ve made this week and our outlook, watch the video here: #bemcentinib #oncology #immunooncology

Today we are pleased to be presenting preliminary data at the EHA Virtual Meeting, showing that #bemcentinib in combination with LDAC has shown encouraging preliminary updated survival data in our Phase II study in relapsed #AML patients. Read more here:

Want to hear more about BerGenBio’s latest COVID-19 updates? Have a read of this in-depth piece from Cormac Sheridan at BioWorld, featuring commentary from CEO Richard Godfrey. #bemcentinib #COVID19.